Non-Cystic Fibrosis Bronchiectasis Market Report 2024

The non-cystic fibrosis bronchiectasis market size has grown strongly in recent years. It will grow from $3.28 billion in 2023 to $3.5 billion in 2024 at a compound annual growth rate (CAGR) of 6.6%. The growth observed in the historic period can be linked to increased incidence and prevalence rates, advancements in diagnostic technologies, a growing elderly population, government support, and funding, improved healthcare infrastructure, heightened awareness of diagnoses, the aging population, and environmental exposures.

The non-cystic fibrosis bronchiectasis market size is expected to see strong growth in the next few years. It will grow to $4.53 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. Anticipated growth in the forecast period is attributed to advancements in personalized medicine, the emergence of new biomarkers, increased investment in respiratory medicine, expanded research and development activities, public health initiatives, the global aging population, and the development of targeted therapies. Key trends expected in the forecast period include the adoption of digital health solutions, a focus on targeted therapies, integration of AI and machine learning, a shift towards home-based care, patient-centered approaches, and the expansion of mobile health (mHealth) solutions.

The non-cystic fibrosis bronchiectasis market is poised for growth due to the increasing incidence of respiratory diseases. These diseases encompass various conditions affecting lung and respiratory function, exacerbated by rising environmental pollution, both outdoors and indoors, such as tobacco smoke. The uptick in respiratory infections presents opportunities for advancing the understanding, diagnosis, and management of non-cystic fibrosis bronchiectasis through targeted interventions and public health initiatives. Recent data from a June 2023 report by the UK's Office for Health Improvement and Disparities highlighted a significant rise in scarlet fever Group A Streptococcus bacteria notifications during the 2022-2023 season in England, underscoring the escalating trend in respiratory illnesses. This trend underscores the anticipated growth in the non-cystic fibrosis bronchiectasis market.

Leading companies in the non-cystic fibrosis bronchiectasis market are increasingly adopting personalized medicine strategies, particularly through innovations such as nebulization solutions, to enhance the efficiency of drug delivery and improve patient adherence. Nebulization technologies represent a cutting-edge approach for precise administration of respiratory medications, thereby boosting treatment adherence and overall therapeutic outcomes. For example, in April 2022, Zambon S.P.A., a prominent pharmaceutical firm based in Italy, secured a designation from the US FDA for CMS I-neb therapy aimed at patients suffering from non-cystic fibrosis bronchiectasis (NCFB). This therapy is investigational and potentially revolutionary as an inhaled treatment for adult NCFB patients infected with P. aeruginosa, a significant milestone in advancing treatment options for this chronic and progressive respiratory condition. The breakthrough designation underscores the accelerated development and regulatory review pathway for CMS I-neb in NCFB.

In November 2023, Chiesi Farmaceutici SpA, an Italian pharmaceutical company, announced a partnership with Haisco Pharmaceutical Group Co., Ltd. This collaboration focuses on Haisco's commercialization of Chiesi's investigational bronchiectasis drug in China. Haisco will provide financial and logistical support to facilitate regulatory approval, marketing, and distribution efforts necessary for introducing the bronchiectasis treatment to the Chinese market. Haisco Pharmaceutical Group Co. Ltd., based in China, specializes in developing treatments for respiratory diseases, including bronchiectasis.

Major companies operating in the non-cystic fibrosis bronchiectasis market are Pfizer Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc (GSK), Boehringer Ingelheim International GmbH, Viatris Inc, Teva Pharmaceutical Industries Ltd, Vertex Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Dr Reddy's Laboratories Ltd, Chiesi Farmaceutici SpA, Lupin Limited, Zambon Company SpA, Sunovion Pharmaceuticals Inc, Insmed Incorporated, Genentech, Zydus Cadila, Santhera Pharmaceuticals, TSRL Inc.

North America was the largest region in the non-cystic fibrosis bronchiectasis market in 2023. The regions covered in the non-cystic fibrosis bronchiectasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-cystic fibrosis bronchiectasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Non-cystic fibrosis bronchiectasis is a persistent condition marked by permanent widening and abnormality of the airways (bronchi) in the lungs. This results from recurrent inflammation and infections, which weaken and damage the walls of the bronchial tubes. Symptoms include mucus buildup, chronic coughing, breathlessness, and frequent respiratory infections. Treatment typically focuses on symptom management, preventing flare-ups, and addressing underlying factors such as bacterial infections or immune system dysfunction.

Diagnosis of non-cystic fibrosis bronchiectasis involves various methods including computed tomography (CT) scans, bronchoscopies, chest X-rays, lung function tests, sputum culture, and blood tests. CT scans provide detailed lung images that help in diagnosing bronchiectasis by revealing the extent and location of lung damage. Treatment options are categorized into surgical interventions, physiotherapy, vaccinations, airway pharmacotherapy, antibiotics, and others. These treatments are utilized across different healthcare settings such as hospitals, clinics, and ambulatory care centers.

The non-cystic fibrosis bronchiectasis market research report is one of a series of new reports that provides non-cystic fibrosis bronchiectasis market statistics, including non-cystic fibrosis bronchiectasis industry global market size, regional shares, competitors with an non-cystic fibrosis bronchiectasis market share, detailed non-cystic fibrosis bronchiectasis market segments, market trends and opportunities, and any further data you may need to thrive in the non-cystic fibrosis bronchiectasis industry. This non-cystic fibrosis bronchiectasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-cystic fibrosis bronchiectasis market consists of revenues earned by entities by providing services such as diagnostic imaging, pulmonary function testing, medical consultations, home healthcare, pulmonary rehabilitation, and management of chronic respiratory infections through pharmaceutical treatments and advanced therapeutic technologies. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-cystic fibrosis bronchiectasis market also includes sales of antibiotics, bronchodilators, mucolytics, inhalers, nebulizers, airway clearance devices, and respiratory monitoring devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.